David Nierengarten
Stock Analyst at Wedbush
(4.46)
# 345
Out of 4,555 analysts
186
Total ratings
48.46%
Success rate
23.09%
Average return
Main Sectors:
Stocks Rated by David Nierengarten
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NUVL Nuvalent | Reiterates: Outperform | $99 | $89.24 | +10.94% | 4 | Sep 9, 2024 | |
| ORKA Oruka Therapeutics | Initiates: Outperform | $40 | $28.00 | +42.86% | 1 | Sep 4, 2024 | |
| SYRE Spyre Therapeutics | Initiates: Outperform | $45 | $29.08 | +54.75% | 1 | Sep 4, 2024 | |
| ORIC ORIC Pharmaceuticals | Reiterates: Outperform | $20 | $9.79 | +104.29% | 6 | Aug 13, 2024 | |
| TCRX TScan Therapeutics | Reiterates: Outperform | $10 | $5.87 | +70.36% | 4 | Aug 13, 2024 | |
| IMNM Immunome | Reiterates: Outperform | $33 | $14.62 | +125.72% | 4 | Aug 13, 2024 | |
| ARTV Artiva Biotherapeutics | Initiates: Outperform | $18 | $12.00 | +50.00% | 1 | Aug 13, 2024 | |
| IRON Disc Medicine | Reiterates: Outperform | $57 | $51.74 | +10.17% | 3 | Aug 9, 2024 | |
| GBIO Generation Bio Co. | Reiterates: Outperform | $5 | $2.17 | +130.41% | 8 | Aug 8, 2024 | |
| INZY Inozyme Pharma | Reiterates: Outperform | $15 | $5.13 | +192.40% | 5 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $519 → $560 | $552.56 | +1.35% | 16 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $24.04 | +41.43% | 2 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $4.36 | +14.68% | 8 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $2 | $1.70 | +17.65% | 4 | May 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $10 | $10.95 | -8.68% | 3 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $5 | $2.97 | +68.35% | 5 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $4.32 | +85.19% | 6 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $34 | $35.58 | -4.43% | 10 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $1.09 | +909.17% | 7 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $36 | $19.89 | +81.00% | 6 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $7 → $5 | $3.45 | +44.93% | 12 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $110 | $86.55 | +27.09% | 2 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $3.68 | +226.09% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $29 | $19.83 | +46.24% | 7 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $23.40 | +143.59% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3 → $1.68 | $0.54 | +212.09% | 1 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2 → $7 | $1.50 | +366.67% | 2 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $70 | $39.20 | +78.57% | 2 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $4 | $7.14 | -43.98% | 6 | Feb 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $14 → $5 | $0.08 | +6,513.76% | 5 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $33 | $15.56 | +112.08% | 2 | Oct 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $6 | $0.88 | +585.24% | 2 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $24 | $8.49 | +182.69% | 5 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $47.51 | -15.81% | 1 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $7 → $4 | $0.74 | +444.00% | 5 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $53 → $46 | $16.61 | +176.94% | 4 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $5 → $13 | $13.37 | -2.77% | 2 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $19 | $5.25 | +261.90% | 3 | Sep 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 | $1.50 | +5,900.00% | 3 | Jan 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.20 | - | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | n/a | $55.80 | - | 6 | Oct 29, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $6.19 | - | 2 | May 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $20.41 | - | 1 | Nov 20, 2017 |
Nuvalent
Sep 9, 2024
Reiterates: Outperform
Price Target: $99
Current: $89.24
Upside: +10.94%
Oruka Therapeutics
Sep 4, 2024
Initiates: Outperform
Price Target: $40
Current: $28.00
Upside: +42.86%
Spyre Therapeutics
Sep 4, 2024
Initiates: Outperform
Price Target: $45
Current: $29.08
Upside: +54.75%
ORIC Pharmaceuticals
Aug 13, 2024
Reiterates: Outperform
Price Target: $20
Current: $9.79
Upside: +104.29%
TScan Therapeutics
Aug 13, 2024
Reiterates: Outperform
Price Target: $10
Current: $5.87
Upside: +70.36%
Immunome
Aug 13, 2024
Reiterates: Outperform
Price Target: $33
Current: $14.62
Upside: +125.72%
Artiva Biotherapeutics
Aug 13, 2024
Initiates: Outperform
Price Target: $18
Current: $12.00
Upside: +50.00%
Disc Medicine
Aug 9, 2024
Reiterates: Outperform
Price Target: $57
Current: $51.74
Upside: +10.17%
Generation Bio Co.
Aug 8, 2024
Reiterates: Outperform
Price Target: $5
Current: $2.17
Upside: +130.41%
Inozyme Pharma
Jul 26, 2024
Reiterates: Outperform
Price Target: $15
Current: $5.13
Upside: +192.40%
Jul 26, 2024
Maintains: Outperform
Price Target: $519 → $560
Current: $552.56
Upside: +1.35%
Jul 23, 2024
Maintains: Outperform
Price Target: $30 → $34
Current: $24.04
Upside: +41.43%
Jun 27, 2024
Reiterates: Neutral
Price Target: $5
Current: $4.36
Upside: +14.68%
May 29, 2024
Downgrades: Neutral
Price Target: $8 → $2
Current: $1.70
Upside: +17.65%
May 24, 2024
Reiterates: Neutral
Price Target: $10
Current: $10.95
Upside: -8.68%
May 24, 2024
Reiterates: Outperform
Price Target: $5
Current: $2.97
Upside: +68.35%
May 14, 2024
Reiterates: Outperform
Price Target: $8
Current: $4.32
Upside: +85.19%
May 10, 2024
Reiterates: Outperform
Price Target: $34
Current: $35.58
Upside: -4.43%
May 10, 2024
Reiterates: Outperform
Price Target: $11
Current: $1.09
Upside: +909.17%
May 10, 2024
Maintains: Outperform
Price Target: $34 → $36
Current: $19.89
Upside: +81.00%
May 10, 2024
Maintains: Neutral
Price Target: $7 → $5
Current: $3.45
Upside: +44.93%
Apr 26, 2024
Reiterates: Outperform
Price Target: $110
Current: $86.55
Upside: +27.09%
Apr 23, 2024
Reiterates: Outperform
Price Target: $12
Current: $3.68
Upside: +226.09%
Apr 23, 2024
Reiterates: Neutral
Price Target: $29
Current: $19.83
Upside: +46.24%
Apr 23, 2024
Reiterates: Outperform
Price Target: $57
Current: $23.40
Upside: +143.59%
Mar 19, 2024
Maintains: Neutral
Price Target: $3 → $1.68
Current: $0.54
Upside: +212.09%
Feb 29, 2024
Upgrades: Outperform
Price Target: $2 → $7
Current: $1.50
Upside: +366.67%
Feb 26, 2024
Maintains: Outperform
Price Target: $60 → $70
Current: $39.20
Upside: +78.57%
Feb 13, 2024
Maintains: Outperform
Price Target: $5 → $4
Current: $7.14
Upside: -43.98%
Dec 8, 2023
Maintains: Equal-Weight
Price Target: $14 → $5
Current: $0.08
Upside: +6,513.76%
Oct 18, 2023
Reiterates: Outperform
Price Target: $33
Current: $15.56
Upside: +112.08%
Aug 17, 2023
Reiterates: Outperform
Price Target: $6
Current: $0.88
Upside: +585.24%
Aug 10, 2023
Reiterates: Outperform
Price Target: $24
Current: $8.49
Upside: +182.69%
Aug 8, 2023
Initiates: Outperform
Price Target: $40
Current: $47.51
Upside: -15.81%
Jul 26, 2023
Maintains: Neutral
Price Target: $7 → $4
Current: $0.74
Upside: +444.00%
Jun 7, 2023
Upgrades: Neutral
Price Target: $53 → $46
Current: $16.61
Upside: +176.94%
May 10, 2023
Upgrades: Outperform
Price Target: $5 → $13
Current: $13.37
Upside: -2.77%
Sep 26, 2022
Maintains: Outperform
Price Target: $11 → $19
Current: $5.25
Upside: +261.90%
Jan 17, 2020
Downgrades: Neutral
Price Target: $90
Current: $1.50
Upside: +5,900.00%
Dec 3, 2019
Downgrades: Neutral
Price Target: n/a
Current: $3.20
Upside: -
Oct 29, 2018
Maintains: Outperform
Price Target: n/a
Current: $55.80
Upside: -
May 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $6.19
Upside: -
Nov 20, 2017
Downgrades: Neutral
Price Target: n/a
Current: $20.41
Upside: -